Purpose

Psoriasis is a chronic autoimmune inflammatory cutaneous disorder, and single-drug therapy is inadequate for curing this disease. Dual-drug therapy with multi-target synergistic effects may be an alternative approach to eradicate psoriasis. This study reports the development of a lipid-polymer hybrid nanoparticle (LPHNP)-based polymeric hydrogel for topical delivery of methoxsalen (MS) and curcumin (CUR) for the management of psoriasis.

Methods

MS-CUR-LPHNPs were prepared using the emulsification solvent evaporation method and incorporated into a Carbopol-940-based polymeric hydrogel for topical application. The antipsoriatic efficacy of the hydrogel was evaluated in an imiquimod (IMQ)-induced psoriasis rat model.

Results

Methoxsalen-co-loaded curcumin lipid-polymer hybrid nanoparticles (MS-CUR-LPHNPs, 206.8 ± 3.2 nm) were successfully prepared with a narrow polydispersity index (PDI = 0.174), negative zeta potential (− 27.1 ± 6.09 mV), and entrapment efficiency of 84.90 ± 0.68%. The polymeric hydrogel showed all the desirable characteristics essential for topical application. The MS-CUR-LPHNP-based polymeric hydrogel achieved superior anti-psoriatic effects in the IMQ-induced psoriasis rat model because of the high dermal retention of dual drugs for an extended period compared to a standard marketed anti-psoriatic formulation.

Conclusion

Therefore, we concluded that the developed MS-CUR-LPHNPs (D6-HNPs) were novel, providing synergistic therapeutic efficacy and promising prospects for the management of psoriasis.

中文翻译：

---

使用基于混合纳米载体的聚合水凝胶局部递送共载姜黄素的甲氧沙林用于治疗银屑病的协同疗法

目的

牛皮癣是一种慢性自身免疫性炎症性皮肤病，单一药物治疗不足以治愈该疾病。具有多靶点协同作用的双药治疗可能是根除银屑病的另一种方法。本研究报告了一种基于脂质聚合物混合纳米颗粒 (LPHNP) 的聚合物水凝胶的开发，用于局部递送甲氧沙林 (MS) 和姜黄素 (CUR) 来治疗牛皮癣。

方法

使用乳化溶剂蒸发方法制备 MS-CUR-LPHNP，并将其掺入基于 Carbopol-940 的聚合物水凝胶中用于局部应用。在咪喹莫特（IMQ）诱导的银屑病大鼠模型中评估了水凝胶的抗银屑病功效。

结果

成功制备了甲氧沙林共载姜黄素脂质聚合物杂化纳米颗粒（MS-CUR-LPHNPs，206.8 ± 3.2 nm），具有窄的多分散指数（PDI = 0.174）、负zeta电位（− 27.1 ± 6.09 mV）和包封性效率为84.90±0.68%。聚合物水凝胶显示出局部应用所必需的所有所需特性。基于 MS-CUR-LPHNP 的聚合水凝胶在 IMQ 诱导的银屑病大鼠模型中取得了优异的抗银屑病效果，因为与标准市售抗银屑病制剂相比，双药物在较长时间内具有较高的真皮保留率。

结论

因此，我们得出的结论是，所开发的 MS-CUR-LPHNPs (D6-HNPs) 是新颖的，为银屑病的治疗提供了协同治疗功效和广阔的前景。